Lacidipine Teva

Lacidipine, the active ingredient in Lacidipine Teva, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to lower elevated blood pressure in adults with hypertension. The medication works by relaxing vascular smooth muscle, thereby reducing systemic vascular resistance.

GNH USA supplies Lacidipine Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our global distribution network ensures consistent quality and regulatory compliance across markets.

Lacidipine belongs to the calcium‑channel blocker class and is used to manage high‑blood‑pressure conditions.

- Essential hypertension: lowers systolic and diastolic pressure, reducing risk of cardiovascular events. - Isolated systolic hypertension: specifically targets elevated systolic values in older patients. - Secondary hypertension: assists in controlling blood pressure when caused by identifiable underlying disorders.

Lacidipine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: sensation of light‑headedness, especially when standing quickly. - Nausea: mild gastrointestinal upset. - Tachycardia: increased heart rate without accompanying arrhythmia.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that may cause fainting. - Angioedema: swelling of face, lips, tongue, or throat requiring urgent care. - Hepatic dysfunction: abnormal liver enzymes indicating possible liver injury. - Myocardial infarction: rare occurrence of heart attack. - Life‑threatening arrhythmia: irregular heart rhythm that can be fatal. - Severe allergic reaction: rash, itching, or anaphylaxis.

Before prescribing Lacidipine, clinicians should consider several safety measures.

- Monitor blood pressure: ensure adequate control without excessive lowering. - Avoid abrupt discontinuation: taper dose to prevent rebound hypertension. - Caution in hepatic impairment: dose adjustment may be required. - Use with caution in elderly patients: increased sensitivity to hypotensive effects. - Avoid concomitant strong CYP3A4 inhibitors: may raise Lacidipine plasma levels. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Lacidipine can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase Lacidipine exposure. - Grapefruit juice: can markedly raise plasma concentrations. - Other potent antihypertensives (e.g., ACE inhibitors, ARBs) used together may cause additive hypotension.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Diuretics: may enhance blood‑pressure‑lowering effect, requiring dose adjustment. - Beta‑blockers: combined use may increase risk of bradycardia or excessive blood pressure reduction.